Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Milestone Pharmaceuticals Inc.    MIST   CA59935V1076

MILESTONE PHARMACEUTICALS INC.

(MIST)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
11/24/2020 11/25/2020 11/27/2020 11/30/2020 12/01/2020 Date
6.68(c) 6.65(c) 6.58(c) 6.7(c) 6.5(c) Last
121 699 48 285 51 160 108 878 200 426 Volume
+2.61% -0.45% -1.05% +1.82% -2.99% Change
More quotes
Financials (USD)
Sales 2020 - - -
Net income 2020 -55,3 M - -
Net Debt 2020 - - -
P/E ratio 2020 -3,26x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -65,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -3,30x
Yield 2021 -
Capitalization 194 M 194 M -
Capi. / Sales 2020 -
Capi. / Sales 2021 -
Nbr of Employees 28
Free-Float 90,4%
More Financials
Company
Milestone Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing etripamil for the treatment of cardiovascular indications. Etripamil is its short-acting calcium channel blocker. It is developing Etripamil as a nasal spray to be administered by the patient to terminate episodes of paroxysmal supraventricular tachycardia (PSVT), as they occur. It... 
Sector
Biotechnology & Medical Research
Calendar
12/03 | 04:20pmPresentation
More about the company
Notations Surperformance© of Milestone Pharmaceuticals Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about MILESTONE PHARMACEUTICALS INC.
11/23MILESTONE PHARMACEUTICALS : to Present at Upcoming Investor Conferences
PR
11/18MILESTONE PHARMACEUTICALS : Announces First Patient Enrolled in RAPID, a Pivotal..
PR
11/13MILESTONE PHARMACEUTICALS : Corporate Presentation
PU
11/13MILESTONE PHARMACEUTICALS : Reports Third Quarter 2020 Financial Results and Pro..
PR
11/11MILESTONE PHARMACEUTICALS : to Present at the Jefferies Virtual London Healthcar..
PR
10/23MILESTONE PHARMACEUTICALS : Announces Pricing of a Public Offering of $45 Millio..
PR
10/22MILESTONE PHARMACEUTICALS : Announces Proposed Public Offering of Common Shares ..
PR
09/08MILESTONE PHARMACEUTICALS : to Present at Upcoming Investor Conferences
PR
08/13MILESTONE PHARMACEUTICALS : Corporate Presentation
PU
08/12MILESTONE PHARMACEUTICALS : Reports Second Quarter 2020 Financial Results and Pr..
PR
08/06MILESTONE PHARMACEUTICALS : to Present at the Canaccord Genuity 40th Annual Grow..
PR
07/29MILESTONE PHARMACEUTICALS : Corporate Presentation
PU
07/23MILESTONE PHARMACEUTICALS : Announces $25 Million Private Placement
PR
07/23MILESTONE PHARMACEUTICALS : Announces Regulatory Guidance and Updated Clinical D..
PR
06/05MILESTONE PHARMACEUTICALS : - Rules of Conduct for Virtual Annual Meetings of Sh..
PU
More news
News in other languages on MILESTONE PHARMACEUTICALS INC.

- No features available -

More news
Chart MILESTONE PHARMACEUTICALS INC.
Duration : Period :
Milestone Pharmaceuticals Inc. Technical Analysis Chart | MIST | CA59935V1076 | MarketScreener
Technical analysis trends MILESTONE PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 13,25 $
Last Close Price 6,50 $
Spread / Highest target 177%
Spread / Average Target 104%
Spread / Lowest Target 23,1%
EPS Revisions
Managers
NameTitle
Joseph G. Oliveto President, Chief Executive Officer & Director
Paul R. Edick Chairman
Jeff Nelson Chief Operating Officer
Amit Hasija CFO & Executive VP-Corporate Development
Francis Plat Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MILESTONE PHARMACEUTICALS INC.-59.40%194
GILEAD SCIENCES, INC.-5.94%76 052
VERTEX PHARMACEUTICALS5.18%59 224
REGENERON PHARMACEUTICALS36.91%54 464
WUXI APPTEC CO., LTD.57.04%38 135
BIONTECH SE236.51%29 915